Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease

  • Robert A Hauser1Email author,
  • Jaroslaw Slawek2,
  • Paolo Barone3,
  • Elisabeth Dohin4,
  • Erwin Surmann5,
  • Mahnaz Asgharnejad6 and
  • Lars Bauer5
BMC NeurologyBMC series – open, inclusive and trusted201616:90

https://doi.org/10.1186/s12883-016-0610-7

Received: 27 November 2015

Accepted: 24 May 2016

Published: 7 June 2016

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
27 Nov 2015 Submitted Original manuscript
30 Dec 2015 Reviewed Reviewer Report - Francesc Vallderiola
10 Jan 2016 Reviewed Reviewer Report - Giovanni Fabbrini
14 Apr 2016 Reviewed Reviewer Report - Enza Maria Valente
28 Apr 2016 Author responded Author comments - Robert A Hauser
Resubmission - Version 2
28 Apr 2016 Submitted Manuscript version 2
5 May 2016 Author responded Author comments - Robert A Hauser
Resubmission - Version 3
5 May 2016 Submitted Manuscript version 3
10 May 2016 Author responded Author comments - Robert A Hauser
Resubmission - Version 4
10 May 2016 Submitted Manuscript version 4
Publishing
24 May 2016 Editorially accepted
7 Jun 2016 Article published 10.1186/s12883-016-0610-7

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Parkinson’s Disease and Movement Disorders Center, USF Health – Byrd Institute, National Parkinson Foundation Center of Excellence, Tampa, USA
(2)
Department of Neurological–Psychiatric Nursing, Medical University of Gdańsk and Department of Neurology, St Adalbert Hospital, Gdańsk, Poland
(3)
Neurodegenerative Disease Center, University of Salerno, Salerno, Italy
(4)
UCB Pharma, Brussels, Belgium
(5)
UCB Pharma, Monheim am Rhein, Germany
(6)
UCB Pharma, Raleigh, USA

Advertisement